2015
DOI: 10.1080/2162402x.2015.1011492
|View full text |Cite
|
Sign up to set email alerts
|

Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen

Abstract: A key to improving cancer immunotherapy will be the identification of tumor-specific “neoantigens” that arise from mutations and augment the resultant host immune response. In this study we identified single nucleotide variants (SNVs) by RNA sequencing of asbestos-induced murine mesothelioma cell lines AB1 and AB1-HA. Using the NetMHCpan 2.8 algorithm, the theoretical binding affinity of predicted peptides arising from high-confidence, exonic, non-synonymous SNVs was determined for the BALB/c strain. The immun… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
32
0

Year Published

2016
2016
2019
2019

Publication Types

Select...
4
1

Relationship

2
3

Authors

Journals

citations
Cited by 26 publications
(33 citation statements)
references
References 33 publications
1
32
0
Order By: Relevance
“…These data are consistent with other pre-clinical studies in which selective depletion of Treg in DEREG mice improved the efficacy of therapeutic vaccination against B16 melanoma [27,28]. Given the recent advances in the identification of tumor neo-antigens [32][33][34][35][36], and progress toward the development of patient-specific cancer vaccines [37,38,41], our findings indicate that targeted modulation of Treg would synergise favorably with other cancer immunotherapies.…”
Section: Discussionsupporting
confidence: 90%
See 1 more Smart Citation
“…These data are consistent with other pre-clinical studies in which selective depletion of Treg in DEREG mice improved the efficacy of therapeutic vaccination against B16 melanoma [27,28]. Given the recent advances in the identification of tumor neo-antigens [32][33][34][35][36], and progress toward the development of patient-specific cancer vaccines [37,38,41], our findings indicate that targeted modulation of Treg would synergise favorably with other cancer immunotherapies.…”
Section: Discussionsupporting
confidence: 90%
“…Given the recent advances in the use of immune based cancer therapies, particularly for solid cancers [30,31], the role of Treg suppression in limiting anti-tumor immunity is of great interest. Technological innovations in next generation sequencing (NGS) have enabled the identification of tumorspecific mutated antigens (i.e., neo-antigens) that are uniquely recognized by the host's immune system [32][33][34][35][36]. The ability to identify immunogenic tumor neo-antigens brings cancer immunotherapy to a position where, the development of a patient-specific anti-cancer vaccine is now a reality [35,37,38].…”
Section: Introductionmentioning
confidence: 99%
“…6 In NSCLC, T-cell responses have been noted against lung cancer tumor-associated antigens (TAAs), such as cancertestis antigens (e.g. 7 However, despite T-cell recognition, tumors still develop due to direct tumor immunoediting, immune cell suppression and/or an inhibitory cytokine milieu. 2 In addition, tumor neoantigens, which are antigens expressed exclusively on tumor cells, have also been shown to initiate antitumor immune responses.…”
Section: Immune Cell Recognition Of Tumor Cells In Lung Cancermentioning
confidence: 99%
“…Numerous sources of TAAs and neoantigens arise due to mutation of oncogenes and suppressor genes, re-expression of foetal proteins and oncogenic viral proteins, and/ or overexpression of normal proteins. 2,7 The ability to identify tumor-specific neoantigens via NGS platforms has reinvigorated anticancer vaccination strategies. To identify mutations, patient tumor samples are sequenced using next-generation sequencing (NGS) technology for aberrations compared to their normal cellular DNA.…”
Section: Neoantigens and Vaccinationmentioning
confidence: 99%
See 1 more Smart Citation